Exploratory analysis In the semaglutide group, %WL did not significantly differ with age, ethnicity, diabetes status, sex, type of surgery, time from surgery (months), baseline meal-stimulated GLP-1 change, postoperative %WL (from date of surgery (DOS) to randomization), maximum %WL achieved after surgery or MBS response (weight regain versus suboptimal post-surgery weight loss)
Their primary research applications are in the realms of type 2 diabetes and obesity
Microdosing Semaglutide has shown promise in optimizing metabolism, supporting weight management, improving cardiovascular health, and promoting cellular wellness
Serious but less common risks include pancreatitis, gallbladder disease, acute kidney injury, and potential thyroid concerns
Active compounds contained 6.9 0.95% THC (~50.6 mg), while placebo compounds contained 0.001 0.000% THC